16.40
전일 마감가:
$16.07
열려 있는:
$16.18
하루 거래량:
1.74M
Relative Volume:
0.96
시가총액:
$2.26B
수익:
$181.74M
순이익/손실:
$-143.97M
주가수익비율:
-11.80
EPS:
-1.39
순현금흐름:
$9.60M
1주 성능:
+8.39%
1개월 성능:
+13.73%
6개월 성능:
-37.74%
1년 성능:
-28.54%
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
ARWR을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
ARWR
Arrowhead Pharmaceuticals Inc
|
16.40 | 2.12B | 181.74M | -143.97M | 9.60M | -1.39 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-06-05 | 개시 | Goldman | Neutral |
2023-12-04 | 개시 | BofA Securities | Buy |
2023-09-19 | 개시 | Citigroup | Neutral |
2023-07-21 | 개시 | TD Cowen | Outperform |
2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
2023-04-26 | 개시 | SMBC Nikko | Outperform |
2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
2023-03-21 | 개시 | Bernstein | Mkt Perform |
2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2022-01-19 | 재개 | Goldman | Buy |
2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
2021-06-04 | 재개 | Robert W. Baird | Neutral |
2021-02-05 | 재확인 | H.C. Wainwright | Buy |
2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2020-12-16 | 개시 | UBS | Buy |
2020-11-19 | 개시 | Citigroup | Buy |
2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
2020-03-17 | 개시 | Goldman | Neutral |
2020-01-21 | 개시 | SVB Leerink | Underperform |
2019-12-13 | 개시 | Oppenheimer | Perform |
2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
2019-11-27 | 재확인 | B. Riley FBR | Buy |
2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
2019-10-03 | 개시 | Robert W. Baird | Outperform |
2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study - Insider Monkey
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity - BioSpace
Arrowhead (ARWR) Kicks Off Clinical Trial for Obesity Treatment ARO-ALK7 | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals Initiates Phase 1/2A Study Of Aro-Alk7 For The Treatment Of Obesity - marketscreener.com
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity | ARWR Stock News - GuruFocus
(ARWR) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - Seeking Alpha
Arrowhead Pharmaceuticals: A Reluctant Sell Rating Explained (Rating Downgrade) (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals to Participate in June 2025 Investor C - GuruFocus
Arrowhead (ARWR) Skyrockets Over 5.7%: Can This Biotech Breakout Propel It Towards $20? - Daily Chhattisgarh News
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences - BioSpace
Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals’ SWOT analysis: RNAi pioneer nears first approval - Investing.com
Arrowhead Pharma (ARWR) Receives Reiterated Buy Rating from HC Wainwright | ARWR Stock News - GuruFocus
BNP Paribas Financial Markets Acquires 32,841 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Research Analysts Offer Predictions for ARWR FY2025 Earnings - Defense World
B. Riley Brokers Boost Earnings Estimates for ARWR - Defense World
Dimensional Fund Advisors LP Sells 86,214 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - Defense World
ARWR: Multiple Value Drivers for Long-Term Growth - Research Tree
Q3 Earnings Forecast for ARWR Issued By Leerink Partnrs - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Arrowhead targets 2025 plozasiran launch with $1.1B cash and clinical pipeline momentum - MSN
ARWR July 18th Options Begin Trading - Nasdaq
ARWR: Multiple Value Drivers for Long-Term Growth… - Yahoo Finance
Citigroup Lowers Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $17.00 - Defense World
UBS Adjusts Price Target for Arrowhead (ARWR) While Maintaining Buy Rating | ARWR Stock News - GuruFocus
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $63 From $71, Maintains Buy Rating - marketscreener.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript - Insider Monkey
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Gap Up on Earnings Beat - Defense World
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR St - GuruFocus
RBC cuts Arrowhead Pharma target to $40; keeps Outperform By Investing.com - Investing.com Canada
Arrowhead Pharma (ARWR) Maintains Neutral Rating but Faces Price Target Cut | ARWR Stock News - GuruFocus
Arrowhead Pharma (ARWR) Maintains Buy Rating with $60 Price Targ - GuruFocus
Arrowhead (ARWR) Price Target Reduced by Citi Analysts | ARWR Stock News - GuruFocus
RBC Adjusts Price Target on Arrowhead Pharmaceuticals to $40 From $42, Maintains Outperform Speculative Risk Rating - marketscreener.com
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... - Yahoo Finance
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highl - GuruFocus
Decoding Arrowhead Pharmaceuticals Inc (ARWR): A Strategic SWOT Insight - GuruFocus
Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals (ARWR) Prepares for Commercial Launch - GuruFocus
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - BioSpace
Earnings call transcript: Arrowhead Pharmaceuticals’ Q2 2025 Surpasses Forecasts - Investing.com Australia
Arrowhead Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arrowhead (ARWR) Advances on New Drug Development and Strategic Funding | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings: EPS of $2 - GuruFocus
Arrowhead Pharmaceuticals Swings to Fiscal Q2 Earnings; Shares Rise After Hours - marketscreener.com
Arrowhead Pharmaceuticals soars 7% on massive earnings beat By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):